Trial Profile
A Phase I/II study of JR-031 for the patients of standard primary treatment-refractory acute graft-versus-host disease (acute GVHD) after hematopoietic stem cell transplantation
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 May 2016
Price :
$35
*
At a glance
- Drugs Remestemcel-L (Primary)
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- Sponsors JCR Pharmaceuticals
- 28 Dec 2012 New trial record